Sigma-Aldrich Corporation SIAL has inked an agreement with XCell Science to introduce genetically engineered human neural differentiated cells along with their culture media for further progress of the research of neurological diseases.
These new products coupled with Sigma-Aldrich’s current portfolio will offer tools for advanced research related to central nervous system disorders, like Alzheimer's disease, Parkinson's disease, autism, schizophrenia, and amyotrophic lateral sclerosis. Also, these will aid drug screening and toxicology applications in the neural space.
The range of isogenic iPSC (induced pluripotent stem cells)-derived neural cells comprise APOE knockout neurons and astrocytes, MAP2 and GFAP reporter lines, and a panel for the evaluation of neurotoxicity and neural protective drug candidates. All cell lines have been tested for their capacity to differentiate into neural cells. Also, they have been approved by genotyping, gene expression, karyotyping, and pluripotency.
These genetically manufactured iPSC-derived neural lines give researchers complete disease models through which they can actually discover the key mechanism of the disease. Additionally, these new lines provide researchers with more dependable disease models for the examination of compound toxicity and efficacy for faster development of drugs at lower costs.
This agreement will leverage XCell’s professional knowledge and Sigma-Aldrich’s global presence and reputation, thereby enabling both the companies and the stem cell community to derive benefits.
Sigma-Aldrich is a Zacks Rank #3 (Hold) stock.
Better-ranked companies in the specialty chemical space include Ferro Corporation FOE, Chemtura Corporation CHMT and Flexible Solutions International Inc. FSI. While Ferro and Flexible Solutions sport a Zacks Rank #1 (Strong Buy), Chemtura carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment